Skip to main content
TipRanks
Go Ultimate75% OFF

Jonathan Alspaugh Insider Profile

11 Followers

Jonathan Alspaugh, Pres. & CFO at Spyre Therapeutics, holds 165.37K shares in Spyre Therapeutics (Ticker: SYRE). Most recently, Jonathan Alspaugh Bought 75,000 shares of Spyre Therapeutics on Mar 15, 2022 for an estimated value of $156.00K.

Jonathan Alspaugh's Trading History

SYRE
Spyre Therapeutics
Mar 15, 2022Pres. & CFOInformative Buy156.00K$17.20M
SYRE
Insider Shares: 165.37K (0.00%)
DateTransactionAmountNo. of SharesPrice per ShareProfitLink to Report
Mar 15, 2022Informative Buy$156.00K75,000$2.08-83.40%
Dec 13, 2021Informative Buy$186.00K50,000$3.72-89.60%
Aug 18, 2021Informative Buy$262.40K40,372$6.49-92.60%

You May Also Like

Jonathan Alspaugh insider profile FAQ

What is the percentage of profitable transactions made by Jonathan Alspaugh?
The percentage of profitable transactions made by Jonathan Alspaugh is 0%.
What is the average return per transaction made by Jonathan Alspaugh?
The average return per transaction made by Jonathan Alspaugh is -88.50%.
What stocks does Jonathan Alspaugh hold?
Jonathan Alspaugh holds: SYRE stocks.
What was Jonathan Alspaugh’s latest transaction?
Jonathan Alspaugh’s latest transaction was an Informative Buy of $156.00K.
What was Jonathan Alspaugh's most profitable transaction?
Jonathan Alspaugh’s most profitable transaction was an Informative Buy of SYRE stock on March 15, 2022. The return on the trade was -83.40%.
What is Jonathan Alspaugh's role in Spyre Therapeutics?
Jonathan Alspaugh's role in Spyre Therapeutics is Pres. & CFO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.